Next Article in Journal
Optimization of Regioselective α-Glucosylation of Hesperetin Catalyzed by Cyclodextrin Glucanotransferase
Previous Article in Journal
Preclinical Pharmacokinetics of C118P, a Novel Prodrug of Microtubules Inhibitor and Its Metabolite C118 in Mice, Rats, and Dogs
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessArticle
Molecules 2018, 23(11), 2884;

Identification and Characterization of NTB451 as a Potential Inhibitor of Necroptosis

BK21PLUS Glocal Education Program of Nutraceuticals Development, Department of Applied Life Science, Graduate School, Konkuk University, Chungju 27478, Korea
Korea Chemical Bank, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea
Department of Biotechnology, College of Biomedical & Health Science, Research Institute of Inflammatory Diseases, 268 Chungwon-daero, Chungju 27478, Korea
Authors to whom correspondence should be addressed.
Received: 13 October 2018 / Revised: 1 November 2018 / Accepted: 4 November 2018 / Published: 5 November 2018
(This article belongs to the Section Materials Chemistry)
Full-Text   |   PDF [3022 KB, uploaded 5 November 2018]   |  


Necroptosis, or caspase-independent programmed cell death, is known to be involved in various pathological conditions, such as ischemia/reperfusion injury, myocardial infarction, atherosclerosis, and inflammatory bowel diseases. Although several inhibitors of necroptosis have been identified, none of them are currently in clinical use. In the present study, we identified a new compound, 4-({[5-(4-aminophenyl)-4-ethyl-4H-1,2,4-triazol-3-yl]sulfanyl}methyl)-N-(1,3-thiazol-2-yl) benzamide (NTB451), with significant inhibitory activity on the necroptosis induced by various triggers, such as tumor necrosis factor-α (TNF-α) and toll-like receptor (TLR) agonists. Mechanistic studies revealed that NTB451 inhibited phosphorylation and oligomerization of mixed lineage kinase domain like (MLKL), and this activity was linked to its inhibitory effect on the formation of the receptor interacting serine/threonine-protein kinase 1 (RIPK1)-RIPK3 complex. Small interfering RNA (siRNA)-mediated RIPK1 knockdown, drug affinity responsive target stability assay, and molecular dynamics (MD) simulation study illustrated that RIPK1 is a specific target of NTB451. Moreover, MD simulation showed a direct interaction of NTB451 and RIPK1. Further experiments to ensure that the inhibitory effect of NTB451 was restricted to necroptosis and NTB451 had no effect on nuclear factor-κB (NF-κB) activation or apoptotic cell death upon triggering with TNF-α were also performed. Considering the data obtained, our study confirmed the potential of NTB451 as a new necroptosis inhibitor, suggesting its therapeutic implications for pathological conditions induced by necroptotic cell death. View Full-Text
Keywords: necroptosis; inhibitor; NTB451; RIPK1 necroptosis; inhibitor; NTB451; RIPK1

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

In, E.-J.; Lee, Y.; Koppula, S.; Kim, T.-Y.; Han, J.-H.; Lee, K.-H.; Kang, T.-B. Identification and Characterization of NTB451 as a Potential Inhibitor of Necroptosis. Molecules 2018, 23, 2884.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top